Preclinical News and Research

RSS

DOD awards $2.24 million grant to study keratin gel in peripheral nerve regeneration

Orthopaedic researchers at Wake Forest University Baptist Medical Center (WFUBMC) have been awarded a $2.24 million four-year grant from the U. S. Department of Defense (DOD) to study the use of keratin gel in the regeneration of damaged peripheral nerves, those in the hands, arms and feet.

2 Dec 2010

Stemline to feature SL-401 clinical efficacy at ASH Annual Meeting

Stemline Therapeutics, Inc. today announced that two abstracts featuring SL-401 clinical efficacy in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), and pre-clinical activity in chronic myeloid leukemia (CML) have been selected for presentation at the upcoming 52nd Annual Meeting of the American Society of Hematology (ASH) to be held in Orlando, FL from December 4-7, 2010.

2 Dec 2010

Tolerx enters collaborative research agreement with Cancer Research Institute

Tolerx, Inc., a biopharmaceutical company developing novel therapies by modulating T cell activity, and the Cancer Vaccine Acceleration Fund (CVAF) a nonprofit program of the Cancer Research Institute established in partnership with the Ludwig Institute for Cancer Research today announced they entered into a collaborative research agreement to support development of Tolerx's drug candidate, TRX518, a monoclonal antibody designed to enhance the immune system by enabling T cells to more effectively attack cancer cells.

2 Dec 2010

PepTcell changes name to SEEK

PepTcell, a leading UK privately-owned drug-discovery group, today announced it is changing its name to SEEK.

1 Dec 2010

Results of pixantrone phase III trial for non-Hodgkin's lymphoma to be presented at Hematology Meeting

Cell Therapeutics, Inc. announced today that Ruth Pettengell, M.D. of St. George's Hospital, University of London, the lead investigator for the PIX 301 EXTEND trial will present end of study results for the pixantrone phase III trial in relapsed/refractory aggressive non-Hodgkin's lymphoma at the 52nd Annual Meeting of the American Society of Hematology on Sunday, December 5, 2010 in Orlando, Florida.

1 Dec 2010

Aushon, LightArray enter strategic partnership to provide multiplex biomarker products and services in China

Aushon BioSystems, Inc., a leading provider of multiplex immunoassay products and services for biomarker discovery, development and analysis announced during the ChinaTrials 2010 Summit in Beijing, China, that it has entered into a partnership with LightArray Biotech Company, Ltd., to provide Aushon's comprehensive suite of multiplex biomarker products and services to pharmaceutical, biotechnical, and academic research institutions located in mainland China.

1 Dec 2010

Icagen, Pfizer select novel compound for further clinical development in Nav1.7 program

Icagen, Inc. today provided an update on its sodium channel program for pain and related disorders which is being conducted in collaboration with Pfizer. As previously reported, the companies recently conducted a clinical study in healthy volunteers of several collaboration compounds targeting the sodium ion channel Nav1.7.

1 Dec 2010

Array BioPharma achieves $10 million clinical research milestone in Celgene collaboration

Array BioPharma Inc. announced today that a $10 million clinical research milestone was achieved in its collaboration with Celgene Corporation. Celgene and Array entered into this research collaboration in September 2007. Array anticipates initiating a Phase 1 dose escalation trial in cancer patients with ARRY-382, a small molecule cFMS inhibitor, during the first quarter of 2011.

1 Dec 2010

NIA awards Aphios Phase I Fast Track SBIR grant for development of novel AD nanodrug

Aphios® Corporation today announced that it was awarded Phase I of a Fast Track SBIR grant from the National Institute of Aging (NIA), National Institutes of Health (NIH) for Developing a Novel Alzheimer's Disease Nanodrug.

30 Nov 2010

New findings offer insights into novel treatment avenue for Crohn's Disease, sarcoidosis

A new finding out in the December 1st issue of Genes & Development offers insight into a new treatment avenue for two painful inflammatory diseases: Crohn's Disease and sarcoidosis.

30 Nov 2010

Accelr8 extends technology evaluation agreement for BACcel rapid diagnostic system

Accelr8 Technology Corporation announced that it extended its technology evaluation agreement for its BACcel™ rapid diagnostic system with a global diagnostics company. The original agreement was announced on June 17, 2010. The essential terms remain unchanged and continue the funding to Accelr8 during the extended project period.

30 Nov 2010

Intellikine and MMRC commence INK128 Phase I trial in multiple myeloma

Intellikine, a leader in the development of small molecule drugs targeting the PI3K/mTOR pathway, and the Multiple Myeloma Research Consortium (MMRC) today announced the initiation of a phase I trial of INK128, a novel, orally-available small molecule kinase inhibitor of the TORC1 and TORC2 complexes, in patients with multiple myeloma.

30 Nov 2010

miRagen and t2cure enter licensing agreement for microRNA 92 technology

miRagen Therapeutics, Inc., a biopharmaceutical company focused on improving patients' lives by developing innovative microRNA (miRNA)-based therapeutics for cardiovascular and muscle disease, and t2cure, a clinical stage biopharmaceutical company developing progenitor cell-based regenerative therapeutics for cardiac or peripheral vascular diseases, announced today that they have entered into a licensing agreement

30 Nov 2010

ImmunoGen initiates IMGN901 Phase I/II clinical trial in SCLC patients

ImmunoGen, Inc., a biotechnology company that develops antibody-based anticancer products using its Targeted Antibody Payload (TAP) technology, today announced the initiation of a randomized Phase I/II clinical trial to evaluate its proprietary product candidate, IMGN901 (lorvotuzumab mertansine), for first-line treatment of small-cell lung cancer (SCLC) in patients with extensive disease.

30 Nov 2010

Researchers conduct real-time metabolic imaging in human patient with prostate tumor

A UCSF research collaboration with GE Healthcare has produced the first results in humans of a new technology that promises to rapidly assess the presence and aggressiveness of prostate tumors in real time, by imaging the tumor's metabolism.

30 Nov 2010

Calistoga to feature data on CAL-101 inhibitor for hematologic malignancies at ASH Annual Meeting

Calistoga Pharmaceuticals, Inc., the leader in the development of delta-isoform-selective phosphatidylinositol 3-kinase (PI3K-delta) inhibitors for the treatment of cancer and inflammatory diseases, today announced the upcoming presentation of clinical and preclinical results supporting the clinical benefit of CAL-101, an oral, PI3K-delta inhibitor, in the treatment of patients with hematologic malignancies.

30 Nov 2010

Zalicus to highlight A2A agonist oncology programs at ASH Annual Meeting

Zalicus Inc. announced today that preclinical data on its discovery of novel A2A agonist oncology programs for the treatment of multiple myeloma and other B-cell malignancies will be highlighted at the 52nd Annual Meeting of the American Society of Hematology in Orlando, FL on December 4-7, 2010.

29 Nov 2010

Micell initiates enrollment in DESSOLVE I clinical trial of MiStent DES

Micell Technologies,™ Inc. today announced it has enrolled at Mercy Hospital in Auckland, New Zealand, the first patient in DESSOLVE I (DES with Sirolimus and a bioabsorbable pOLymer for the treatment of patients with de noVo lEsions in the native coronary arteries), a first-in-human clinical trial of the company's investigational MiStent™ Drug Eluting Coronary Stent System (MiStent DES).

29 Nov 2010

JAK3 pathway highlighted as leukemia target

An intriguing study published in Expert Review of Anticancer Therapy has revealed that the signaling protein JAK3 represents a viable target in the treatment of a broad range of B-lineage cancers, including acute lymphoblastic leukemia (ALL).

28 Nov 2010

Personalized oncology requires new paradigm for drug development, experts say

Millions of cancer patients worldwide may soon be able to receive more effective, personalized treatments for their disease thanks to developments in the understanding of cancer biology, experts will say at the Cancer Biology for Clinicians Symposium organized by the European Society for Medical Oncology (ESMO) in Nice this week.

25 Nov 2010

Preclinical News and Research

DOD awards $2.24 million grant to study keratin gel in peripheral nerve regeneration

Stemline to feature SL-401 clinical efficacy at ASH Annual Meeting

Tolerx enters collaborative research agreement with Cancer Research Institute

PepTcell changes name to SEEK

Results of pixantrone phase III trial for non-Hodgkin's lymphoma to be presented at Hematology Meeting

Aushon, LightArray enter strategic partnership to provide multiplex biomarker products and services in China

Icagen, Pfizer select novel compound for further clinical development in Nav1.7 program

Array BioPharma achieves $10 million clinical research milestone in Celgene collaboration

NIA awards Aphios Phase I Fast Track SBIR grant for development of novel AD nanodrug

New findings offer insights into novel treatment avenue for Crohn's Disease, sarcoidosis

Accelr8 extends technology evaluation agreement for BACcel rapid diagnostic system

Intellikine and MMRC commence INK128 Phase I trial in multiple myeloma

miRagen and t2cure enter licensing agreement for microRNA 92 technology

ImmunoGen initiates IMGN901 Phase I/II clinical trial in SCLC patients

Researchers conduct real-time metabolic imaging in human patient with prostate tumor

Calistoga to feature data on CAL-101 inhibitor for hematologic malignancies at ASH Annual Meeting

Zalicus to highlight A2A agonist oncology programs at ASH Annual Meeting

Micell initiates enrollment in DESSOLVE I clinical trial of MiStent DES

JAK3 pathway highlighted as leukemia target

Personalized oncology requires new paradigm for drug development, experts say

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest Life Science News